<DOC>
	<DOCNO>NCT01864941</DOCNO>
	<brief_summary>To investigate safety tolerability balloon venoplasty compare sham Multiple Sclerosis patient Chronic Cerebrospinal Venous Insufficiency ( CCSVI ) measure adverse event occur within 48 week procedure .</brief_summary>
	<brief_title>Interventional Clinical Trial CCSVI Multiple Sclerosis Patients</brief_title>
	<detailed_description>Overview study objective : - To determine safety tolerability venoplasty CCSVI Multiple Sclerosis ( MS ) . - To determine short term long term impact validate patient measure physician radiologic report MS outcome . - To determine short term long term recurrence rate CCSVI vein treat venoplasty</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis Relapsing Remitting Multiple Sclerosis ( RRMS ) Secondary Progressive MS accord McDonald criterion 2010 Age 18 65 year inclusive Neurostatus ( EDSS ) score screen 0 6.5 Fulfill ultrasound criterion CCSVI Previous venoplasty and/or stenting extra cranial venous system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>CCSVI</keyword>
	<keyword>Zamboni</keyword>
	<keyword>catheter venography</keyword>
	<keyword>balloon angioplasty</keyword>
</DOC>